X

Trial Profile

A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ivacaftor/tezacaftor (Primary) ; VX 118 (Primary) ; VX 828 (Primary) ; Itraconazole; Midazolam
Indications Cystic fibrosis
Focus Adverse reactions; Pharmacokinetics
Sponsors Vertex Pharmaceuticals

Most Recent Events

20 Jan 2025 Protocol has been amended , number of arms changed from 5 to 8, VX-828 in Triple Combination (TC) with TEZ/VX-118 arms has been added to trial.
20 Jan 2025 Planned number of patients changed from 159 to 225.
20 Jan 2025 Planned End Date changed from 1 Apr 2025 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com